Results 61 to 70 of about 11,732 (171)

Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.

, 2017
245 Background: While FOLFIRINOX is a standard treatment option for advanced pancreas cancer there is little data describing utilization and effectiveness in routine clinical practice.
Safiya Karim, Tim Asmis, James Joseph Biagi, Christopher M. Booth, Jina Zhang-Salomons   +4 more
core   +1 more source

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma [PDF]

, 2020
Background. Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens.
MD T Peter Kingham, MD Karyn A Goodman, MD Ronald P Dematteo, MD Peter J Allen, MD P J Allen, MD Michael I D'angelica, Richard Kinh, MD, PhD Gian Do, MD Alexandre Doussot, PhD Mithat Gönen, MD Eran Sadot, Ann Surg Oncol, MD William R Jarnagin, MD Eileen M O'reilly, MD, PhD Laura H Tang, MD Maeve A Lowery   +15 more
core  

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis

Journal of International Medical Research, 2022
Objective To undertake a meta-analysis of the treatment effects of different second-line chemotherapy regimens compared with FOLFIRINOX (FOL [folinic acid], F [fluorouracil], IRIN [irinotecan], OX [oxaliplatin]) after failure of gemcitabine-based first ...
Wenjie Lu, Lantian Wang, Xiawei Li, Kezhong Tang   +3 more
doaj   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3397-3406, October 2026.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Characteristics of the 123 patients treated with FOLFIRINOX.

, 2018
Characteristics of the 123 patients treated with FOLFIRINOX.
Teresa Magnes (4234120), Bernhard Jaud (5949761), Lukas Weiss (4234126), Lukas Ratzinger (5949758), Alexander Egle (182284), Konstantin Schlick (3461021), Richard Greil (182286), Thomas Melchardt (4234132)   +7 more
core   +1 more source

A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy

Neoplasia: An International Journal for Oncology Research
Background: Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a chemotherapy associated with high toxicity rates and variable efficacy.
Casper W.F. van Eijck, Sergio Sabroso-Lasa, Gaby J. Strijk, Dana A.M. Mustafa, Amine Fellah, Bas Groot Koerkamp, Núria Malats, Casper H.J. van Eijck   +7 more
doaj   +1 more source

Basal Marker ΔNp63α Is Enriched in Pancreatic Cancer Metastases but Not in Primary Tumors Post‐Chemotherapy

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Cancer cells within a single pancreatic ductal adenocarcinoma (PDAC) are most often heterogeneous in their expression of the basal or classical transcriptional program. Predominance of the basal subtype has been associated with poorer patient outcomes and increased resistance to chemotherapy.
Daniel H. Ryan, Yuuki Ohara, Michael J. Kruhlak, Xianyu Zhang, Miao Lin, Chin‐Hsien Tai, Christine Alewine   +6 more
wiley   +1 more source

Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma

Journal of Surgical Oncology, Volume 134, Issue 5, Page 631-638, October 2026.
ABSTRACT Introduction Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized
Mohammed O. Suraju, Brian Longbottom, Jasmine A. Peterson, Terry Hayes, Kiers Brevik, Sean Y. Kim, Paolo Goffredo, Imran Hassan, Hassan Aziz, Carlos H. F. Chan   +9 more
wiley   +1 more source

Ellagic Acid Enhances RSL3‐Induced Ferroptosis by Inhibiting the Nrf2/HO‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Ellagic acid potentiates RSL3‐induced ferroptosis in PANC‐1 by suppressing the Nrf2/HO‐1 antioxidant defense axis via p38 MAPK activation and Keap1 upregulation. In PDAC cells, constitutive Nrf2/HO‐1 signaling establishes a robust antioxidant shield (GPX4, HO‐1) that limits lipid ROS accumulation and confers ferroptosis resistance.
Jianhua Bai, Yihe Dai, Chern Ein Oon, Pingping Hu, Jia Luo, Jiang Han, Liman Yang, Amirabas Bostani, Zhenhao Fei, Yun Jin   +9 more
wiley   +1 more source

Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison

, 2020
Purpose: To compare survival after CT-guided percutaneous irreversible electroporation (IRE) and folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) chemotherapy versus FOLFIRINOX only in patients with locally advanced pancreatic cancer (
Derksen, Tyche C., Besselink, Marc G., Wilmink, Johanna W., Meijerink, Martijn R., Kazemier, Geert, Vogel, Jantien A., Scheffer, Hester J., Ruarus, Alette H., de Jong, Marcus C., Busch, Olivier R., Sorgedrager, Natasha S., Vroomen, Laurien G., Puijk, Robbert S., van Lienden, Krijn P., van Veldhuisen, Eran   +14 more
core   +1 more source